Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Nocturia - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 39 | Code: MRS - 18149


Global Markets Directs, Nocturia Pipeline Review, H1 2015, provides an overview of the Nocturias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nocturia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nocturia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Nocturia
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Nocturia and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Nocturia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Nocturia pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Nocturia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Nocturia Overview 6
Therapeutics Development 7
Pipeline Products for Nocturia - Overview 7
Pipeline Products for Nocturia - Comparative Analysis 8
Nocturia - Therapeutics under Development by Companies 9
Nocturia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Nocturia - Products under Development by Companies 13
Nocturia - Companies Involved in Therapeutics Development 14
Allergan, Inc. 14
Ferring International Center S.A. 15
Sumitomo Dainippon Pharma Co., Ltd. 16
Vantia Therapeutics 17
Nocturia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
afacifenacin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ASP-7035 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
desmopressin acetate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FE-999309 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
fedovapagon - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Paxerol - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Nocturia - Recent Pipeline Updates 33
Nocturia - Dormant Projects 35
Nocturia - Product Development Milestones 36
Featured News & Press Releases 36
Feb 02, 2010: Vantia Therapeutics Initiates Phase IIb Clinical Trial Of VA106483 For Nocturia 36
Jun 29, 2009: Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect In Phase IIa Trial In Nocturia 36
Mar 24, 2009: Vantia Therapeutics' VA106483 Completes Phase IIa Trial 37

Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables

Number of Products under Development for Nocturia, H1 2015 7
Number of Products under Development for Nocturia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Nocturia - Pipeline by Allergan, Inc., H1 2015 14
Nocturia - Pipeline by Ferring International Center S.A., H1 2015 15
Nocturia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 16
Nocturia - Pipeline by Vantia Therapeutics, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 20
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Nocturia Therapeutics - Recent Pipeline Updates, H1 2015 33
Nocturia - Dormant Projects, H1 2015 35

List of Figures

Number of Products under Development for Nocturia, H1 2015 7
Number of Products under Development for Nocturia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Top 10 Targets, H1 2015 19
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing